(E)-3-((1H-indazol-6-yl)methylene)-7-aminoindolin-2-one | 1168721-50-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: (E)-3-((1H-indazol-6-yl)methylene)-7-aminoindolin-2-one
• 英文别名: (3E)-7-amino-3-(1H-indazol-6-ylmethylidene)-1H-indol-2-one
• CAS: 1168721-50-3
• 化学式: C₁₆H₁₂N₄O
• 分子量: 276.297
• InChiKey: CUMYLIHLEJSTCE-WUXMJOGZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.64
• 重原子数：
  21.0
• 可旋转键数：
  1.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.8
• 氢给体数：
  3.0
• 氢受体数：
  3.0

反应信息

• 作为产物：
  描述：

  1H-吲唑-6-甲醛 、 7-氨基吲哚酮 在 哌啶 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以28%的产率得到(E)-3-((1H-indazol-6-yl)methylene)-7-aminoindolin-2-one
  参考文献：
  名称：

  [EN] INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER
  [FR] DÉRIVÉS D'INDOLMONE À SUBSTITUTION INDAZOLYLE, BENZIMIDAZOLYLE, BENZOTRIAZOLYLE EN TANT QU'INHIBITEURS DE KINASES UTILISÉS DANS LE TRAITEMENT DU CANCER

  摘要：

  公开号：

  WO2009079767A9

文献信息

• INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER
  申请人：Pauls Heinz W.

  公开号：US20110065702A1

  公开（公告）日：2011-03-17

  The present invention is directed to a compound is represented by Structural Formula (A):or a pharmaceutically acceptable salt therof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.

  本发明涉及一种化合物，其结构式表示为(A)或其药学上可接受的盐。本发明还涉及一种药物组合物，包括上述结构式(A)所表示的化合物或其药学上可接受的盐，以及药学上可接受的载体或稀释剂。本发明还揭示了一种治疗患有癌症的受试者的方法，其中该方法包括给予上述结构式(A)所表示的化合物或其药学上可接受的盐的治疗有效量。
• Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
  申请人：Pauls Heinz W.

  公开号：US08765748B2

  公开（公告）日：2014-07-01

  The present invention is directed to a compound is represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.

  本发明涉及一种由结构式（A）表示的化合物或其药学上可接受的盐。本发明还涉及一种药物组合物，包括上述结构式（A）表示的化合物或其药学上可接受的盐，以及药学上可接受的载体或稀释剂。本发明还揭示了一种治疗癌症患者的方法，其中该方法包括给予上述结构式（A）表示的化合物或其药学上可接受的盐的治疗有效量。
• INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLMONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER
  申请人：University Health Network

  公开号：EP2235004A1

  公开（公告）日：2010-10-06
• US8765748B2
  申请人：——

  公开号：US8765748B2

  公开（公告）日：2014-07-01
• [EN] INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLMONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS D'INDOLMONE À SUBSTITUTION INDAZOLYLE, BENZIMIDAZOLYLE, BENZOTRIAZOLYLE EN TANT QU'INHIBITEURS DE KINASES UTILISÉS DANS LE TRAITEMENT DU CANCER
  申请人：UNIV HEALTH NETWORK

  公开号：WO2009079767A1

  公开（公告）日：2009-07-02

  The present invention is directed to a compound is represented by Structural Formula (A):or a pharmaceutically acceptable salt therof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.